Semaglutide vs Tirzepatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSemaglutideTirzepatide
What it is

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1

A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.5

FDA status

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy1,2,3,4

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,2,3,4

Is semaglutide FDA-approved?

FDA-approved

FDA-approved as Mounjaro and Zepbound5,6,7

FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.5,6,7

Is tirzepatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.1
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.1
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.1

Large randomized human trials

  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.5
  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.5
  • Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.5
  • Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.9,10
Records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

108 ClinicalTrials.gov records and 75 PubMed records collected

Area of study

Metabolic and weight, Heart and blood vessels, Liver1

Metabolic and weight5

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.11
  2. DailyMed publishes the Wegovy label version cited on this page.1
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.12
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.11
  2. DailyMed publishes the Zepbound label version cited on this page.5
  3. FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  6. 6
    Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  10. 10
    Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  11. 11
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  12. 12
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026